Overexpression of the gene encoding cPLA2α (PLA2G4A) has been reported in patient samples from different solid cancers such as breast cancer [10], hepatocellular carcinoma [11], cervical cancer [12], prostate cancer [13], and lung cancer [14], as well as hematological cancers such as acute myeloid leukemia (AML) [15,16] and B-cell lymphocytic leukemia (B-CLL) [17]. This evidence concerns the gene PLA2G4A and hematopoietic and lymphoid cell neoplasm.